(N-Stearyl, Norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines

H. Zia, J. Leyton, M. Casibang, V. Hau, D. Brenneman, M. Fridkin, I. Gozes, T. W. Moody*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The effects vasoactive intestinal peptide (VIP) antagonists were investigated on pancreatic cancer cell lines. (N-Stearyl, Norleucine17) VIP hybrid ((SN)VIPhyb) inhibited 125I-VIP binding to human Capan-2 cells with an IC50 value of 0.01 μM whereas VIPhybrid had an IC50 value of 0.2 μM. By RT-PCR and Northern blot, VPAC1 receptor mRNA was detected in CAPAN-2 cells. One μM (SN)VIPhyb and 10 μM VIPhyb inhibited the ability of 30 nM VIP to elevate cyclic AMP and increase c-fos mRNA. (SN)VIPhyb, 1 μM inhibited the clonal growth of CAPAN-2 cells in vitro. In vivo, (SN)VIPhyb (10 μg/day s.c.) inhibited CAPAN-2 xenograft growth in nude mice. These results indicate that (SN)VIPhyb is a pancreatic cancer VPAC receptor antagonist.

Original languageEnglish
Pages (from-to)379-387
Number of pages9
JournalLife Sciences
Volume66
Issue number5
DOIs
StatePublished - 17 Dec 1999

Funding

FundersFunder number
Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentZ01HD000047

    Keywords

    • Pancreatic cancer
    • VIP antagonist
    • c-fos
    • cAMP

    Fingerprint

    Dive into the research topics of '(N-Stearyl, Norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines'. Together they form a unique fingerprint.

    Cite this